Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Risedronic Acid × 90 days × Clear all
NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Harbin Medical University

Phase 2 Active not recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡